CD8A and neoplasm: The slow persistent release of the antigen coupled with the local inflammation induced by the emulsion itself can actually result in the sequestration of primed CD8+ T cells at the injection site, when using short peptides, leading to limited T cell homing to the tumor and T cell tolerance (146–149).